Navigation Links
Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan
Date:9/2/2014

LONDON, Sept. 2, 2014 /PRNewswire/ -- Drug delivery technologies that improve access and overall efficacy are becoming an essential part of the entire drug development process. Pharmaceutical companies are particularly investing billions of dollars in new vaccine delivery technologies in a bid to move away from needles and syringes to skin delivery procedures.

New analysis from Frost & Sullivan, Needle-Free Nanopatch Vaccines, finds that though the needle-free delivery sector currently makes up a small fraction of the total drug delivery market, the next five to ten years will see transdermal and intradermal systems (patches and degradable implants), fast-dissolving tablet vaccines, inhalers, and pulmonary delivery methods change the vaccine industry.

While certain forms of needle-free vaccines, such as liquid jet injection, gene guns and micro-needles are already in use, the cell damage caused during administration and the inability to consistently and directly deliver vaccines renders such delivery methods inefficient. Nevertheless, this inefficiency opens doors for vaccine manufacturers to create and commercialise a needle-free system that is not fraught with challenges.

"The delivery of drugs through needle-free devices is gaining acceptance owing to the availability of more formulations for needle-free deliveries," said Frost & Sullivan Healthcare Research Analyst Swathi Allada. "Significant advancements have been made, most of which have centred on addressing patient comfort levels and increasing the adoption of self-injectable therapies."

The development of thermostable vaccines with a long shelf life is another area of focus for many vaccine manufacturers, especially for those marketing to nations where cold-chain storage is an issue. The nanopatch, for instance, eliminates the need for refrigeration as the thermostable vaccine is formulated in dry form, making transportation significantly cheaper than traditional needles.

The nanopatch is a micro-needle patch comprising of little, densely packed micro-projections with a defined geometry. Smaller than a postage stamp – and getting smaller – it is capable of directly depositing vaccine to thousands of skin immune cells without causing damage to the cell membrane in the process.

"The nanopatch achieves precise, controlled and consistent skin penetration along with rapid dissolution and diffusion of the vaccine," noted Allada. "Early stage tests conducted on mouse models have shown that the nanopatch-delivered flu vaccine is effective even with 1/150th of the dose normally given through a traditional syringe."

With successful testing in animals, clinical trials on humans will need to be wrapped up to attain Food and Drug Administration approval. Once this happens, the technology will rapidly gain traction both among patients and physicians, ultimately changing the course of vaccine delivery globally.

For more information on this study, please email Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

This Market Insight, Needle-Free Nanopatch Vaccines, is part of the Advanced Medical Technologies Growth Partnership Service program. The Insight covers a range of needle-free vaccine deliveries, discussing drivers for adoption and application scope. The study also details the development and potential of the nanopatch as well as its impact on the vaccine industry.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com

Logo - http://photos.prnewswire.com/prnh/20140902/141801


'/>"/>
SOURCE Frost & Sullivan
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Needle-Free Delivery: Technology and Market Forecast 2014-2024
2. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
3. Increased Dosage of Needle-Free Erectile Dysfunction Medication TriMix-gel Now Available through KRS Global Biotechnology
4. Global Needle-Free Drug Injection Systems and Safety Syringes Industry
5. Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis
6. BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
7. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials
8. Global Transdermal Drug Delivery Market 2014-2018: Key Vendors are ANI Pharmaceuticals, Antares Pharma, Bayer, Janssen and Novartis
9. Driven By Product Innovations, the U.S. Drug Delivery Device Market Will Reach Over $4.5 Billion by 2022
10. BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
11. Digital Pathology Market by Slide Scanners, Analytics, Delivery Modes & Whole Slide Image Storage - Global Forecasts & Trends to 2018. In New Research Report Available at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
Breaking Medicine News(10 mins):